COVID-19

View All

Aurinia's Lupkynis for Lupus; Toripalimab; Merck’s Covid-19 Vaccines fail
Aurinia’s Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Find More

Anxiety and COVID-19
We’re all in this together!

Overcoming Anxiety in the pandemic times!! The past year has been a tough journey for all of us. It has taught us many lessons that are going to stay with us for the whole of our lives. Thus, DelveInsight has decided to take you all on a ride full of experiences - some bitter and some sweet - yet with the power ...

Find More

Historic win for Pfizer's COVID-19 Vaccine; Alexion Buyout; and more
FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development...

Find More

recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent
Novartis’ COVID-19 deal; Shattered hopes for Remdesivir; Lilly’s R&D pact with Precision; Innovent’s Humira Biosimilar

Novartis bags Mesoblast's cell therapy, Remestemcel-L for COVID-19 ARDS The COVID-19 pandemic has put tremendous pressure on scientists to develop a safe and effective vaccine as early as possible. According to the WHO, there are currently more than 100 COVID-19 vaccine candidates under development, with several...

Find More

pharma-news-for-roche-prestige-covid-19
Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19

Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia   The US FDA has granted its full approval to Venclexta (venetoclax) for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older who are unfit for intensive induction chemotherapies.  The approval is based on the res...

Find More

recent-pharma-news-and-updates-for-moderna-pfizer-myovant-alnylam
Brain’s immune cells research update; Moderna’s COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant’s relugolix falls short in metastatic prostate cancer; Alnylam’s lumasiran phase 3 result

The immune cells of the brain could treat neurodegenerative diseases Human behavior relies on the stimulation and inhibition of neurons, and scientists have long considered that neurons are mainly responsible for maintaining this circuit of activity in balance. However, now, a research team led by the Icahn Scho...

Find More

recent-pharma-news-and-updates-for-gilead-roche-celleron-f2g
Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug

Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Bla...

Find More

COVID-19-vaccine-development-updates-in-india
In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player

India registered its first COVID-19 case on 30-January-2020 in Kerala. The cases since then are on a continuous rise. The Government of India in order to contain the spread of novel coronavirus rolled out several guidelines and precautionary measures. The situation worldwide was so serious that the whole nation was...

Find More

Pharma News | COVID-19 News | Cancer News
Merck, Dewpoint’s HIV Pipeline; Pfizer, BioNTech ‘s COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer

Merck Collaborates with Dewpoint Therapeutics to Cure HIV with Condensates   Merck has forged a collaboration with Boston-based Dewpoint Therapeutics to treat HIV using Dewpoint’s proprietary platform for condensate-based drug discovery.Under the terms of the agreement, Dewpoint is eligible for receiving ...

Find More

Coronavirus-COVID-19-Vaccine-Candidates
The Most Promising COVID-19 Vaccine Candidates In The Pipeline To Watch Out For

Coronavirus pandemic has infected over 10 million people worldwide with over half a million casualties. The lock-down and other restriction measures such as social distancing have somehow slowed down the virus spread initially. But these steps have caused many serious humanitarian and economic consequences. Countri...

Find More